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ABSTRACT
Objective: The pharmacoeconomic guidelines available in the literature or
promulgated in many countries are either vague or silent about how drug
costs should be established or measured so an international comparison of
cost-effectiveness analysis (CEA) results can be made. The objective of this
report is to provide guidance and recommendations on how drug costs
should be measured for CEAs done from an internationally comparative
perspective.
Methods: Members of the International Society for Pharmacoeconomics
andOutcomes Research (ISPOR) Task Force onGoodResearch Practices—
Use of Drug Costs for Cost Effectiveness Analysis (Drug Cost Task Force
[DCTF]) subgroup from several countries were experienced developers or
users of CEA models, and worked in academia, industry, and as advisors to
governments. They solicited comments on drafts from a core group of 174
external reviewers andmore broadly, from themembers of the ISPOR at the
ISPOR 12th Annual International meeting and via the ISPOR Web site.
Results: Drug units should be standardized in terms of volume of active
ingredient, regardless of packaging and dosing strength variations across
countries. Drug costs should be measured in local currency per unit of
active ingredient and should be converted to other currencies using sensi-
tivity analyses of purchasing power parities (PPP) and exchange rates,
whichever is more appropriate. When using drug prices from different
years, the consumer price index for the local currency should be applied
before the PPP and/or exchange rate conversion.
Conclusion: CEA researchers conducting international pharmacoeco-
nomic analysis should tailor the appropriate measure of drug costs to
the international perspective, to maintain clarity and transparency
on drug cost measurement in the context of international drug
comparison and report the sensitivity of CEA results to reasonable cost
conversions.
Keywords: drug cost, health technology assessment, pharmacoeconomics.
Background to theTask Force
The International Society for Pharmacoeconomics and Outcomes
Research (ISPOR) Task Force on Good Research Practices—Use
of Drug Costs for Cost Effectiveness Analysis (DCTF) was rec-
ommended by the ISPOR Health Science Policy Council on
December 13, 2004 and was approved by the ISPOR Board of
Directors on May 15, 2005. Because how drug costs should be
measured for cost-effectiveness analyses (CEAs) depend on the
perspectives, ﬁve Task Force subgroups were created to develop
drug costs standards from the societal, managed care, US gov-
ernment, industry, and international perspective. This report is
part VI: an international perspective (one of six reports from this
ISPOR Task Force on Good Research Practices—Use of Drug
Costs for Cost Effectiveness Analysis [DCTF]). The other reports
(part I: issues and recommendations; part II: a societal perspec-
tive; part III: a managed care perspective; part IV: US government
perspective; and part V: industry perspective) are also published
in this issue of Value in Health (volume 13, issue 1). This DCTF
subgroup met to develop core assumptions and an outline before
preparing a draft report. The Task Force subgroups held open
forums and/or group leader breakfast meetings at the ISPOR
Annual International Meetings and European Congresses. The
draft report was circulated to 174 Task Force primary reviewers
(who were self-identiﬁed from a broad range of perspectives).
After this review, a new draft was prepared and made accessible
for broader review by all ISPOR members. Comments for these
reports by Task Force primary reviewers and ISPOR membership
are published at the ISPOR Web site. All opinions reﬂect those of
the authors and not necessarily their afﬁliations.
We aim to review pharmaceutical price and cost issues from
our subgroups’ designated perspective (i.e., ex-US perspective).
As such, we will review current practices from literature articles,
including the Organization for Economic Cooperation and
Development and developing countries, which usually have very
little presence in the research and development (R&D) of new
chemical entities. In recent years, considerable attention has been
focused on pharmaceutical prices in emerging markets [1].There-
fore, in addition to the literature search, a panel of experts (J.
Ahn, F. Augustvoski, S. Hu, and S. Li) from South Korea, Argen-
tina, China, and Australia, respectively, has provided input on
two questions: 1) How are drug prices set in your respective
country? and 2) What are the sources of drug cost estimates used
in pharmacoeconomic studies in your respective country and
what are the key issues?
Introduction
Since the early 1990s when Australia proposed guidelines requir-
ing CEA of new pharmaceutical products, there has been an
increase in the number of pharmacoeconomic studies performed
[2]. One of the important parameters of these studies is drug
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costs, including both the cost of the study drug and its compara-
tors. In addition, the cost of concomitant drugs used to treat
adverse events can be an important component of the evaluation.
Unlike other parameters, there have been few studies on how
drug costs are estimated. Nevertherless, there have been many
methodological questions proposed concerning these studies, for
example, whether the methods are consistent across studies and
theoretically correct.
The costs of drug regimens involve not only the estimation of
the drug price but also the impact of any wholesale discounts,
pharmacy costs, and assumptions about wastage (owing to
package or vial size). This becomes a major problem when inter-
national comparisons are performed because these values differ
across countries, and many countries do not have the same drug
compounds, dose sizes, strengths, or packaging.
There is also an increase in theoretical literature often linked
to discussions about patent protection that suggests market
prices for drugs are not good approximations for social oppor-
tunity costs (the theoretically correct estimate of cost to be used
in economic evaluations undertaken from the societal perspec-
tive). Issues of importing price controls, parallel trade, and the
globalization of the pharmaceutical market make these pricing
issues even more relevant. For example, four different method-
ological approaches to pharmaceutical price regulation were
found in the European Union countries, including ﬁxed pricing,
cost-effectiveness pricing, proﬁt controls, and reference pricing
[3]. Another study looking at pricing issues showed the potential
cost savings to Ireland if an alternative pricing mechanism was
used [4].
For years, in countries around the world, such as Australia,
The Netherlands, and Canada, pharmacoeconomic studies have
been used by governments to set domestic prices or to evaluate
alternative regulatory systems [5]. With an increase in the use of
economic evaluations by governments around the world, there is
an urgency and need to develop a standard for drug costs in
pharmacoeconomic studies from the international perspective.
Argentina
Unlike their neighbor Brazil [6], there is no formal drug price
regulation in Argentina, and sale prices are set according to
market rules. The country does not currently have cross-
referencing pricing mechanisms. Nevertheless, there are several
mechanisms that regulate drug prices. Regarding national refer-
ence pricing, around 200 essential drugs are included on the
formulary for the Social Health Insurance Package (PMO). This
formulary is regulated by the Superintendency of Health [7].
Also, generic prescribing is strongly enforced by a congress law
passed in 2004 [8,9]. One of the problems with drug prices is that
not all prescription drug costs are available through publicly
available sources (Manual Farmacéutico, Kairos, IMS). High-
cost drugs are handled by direct selling, escape price controls,
and monitoring (some examples are imatinib, saquinavir, beva-
cizumab, sorafenib) [10]. A recent proposal by the Superinten-
dency of Health created a drug observatory of the National
Health Insurance (NHI) System [11]. During recent years, agree-
ments between the government and industry involved reducing
the price of more than 200 drugs and regulating gradual price
increases over time. Nevertheless, there is no clear evidence that
these agreements are being honored [10].
Until 2005, pharmacoeconomic evidence was recommended
to include new drugs in the Social Health Insurance Package
(PMO), but this is not true anymore. Nevertheless, currently,
pharmacoeconomic evidence is informally considered by many
stakeholders in the macro-level and meso-levels [12]. Main
sources of drug costs for the public sector come from publicly
available data from manufacturers’ bids. Nevertheless, in the
case of evaluations from the social insurance or private HMO
perspectives, costs are estimated by different payers, or other-
wise, from available sales price sources (Manual Farmacéutico,
Kairos, IMS), and a variable rebate is applied according to the
sector. Also, there is an independent and publicly available
Health Care Costs Database in Argentina for researchers per-
forming economic evaluations [13].
Australia
In the Australian health-care system, drugs that have been
approved for marketing, after going through the evaluation
process for efﬁcacy, safety, and quality by the Therapeutic Goods
Administration, would usually apply for inclusion in the Phar-
maceutical Beneﬁts Scheme (PBS) funded by the Commonwealth
Government at the earliest opportunity. The inclusion of a drug
into the PBS qualiﬁes the drug to be reimbursed by the Com-
monwealth Government for its use in the community and private
hospital settings. The recommendation for inclusion is made to
the minister of health through an independent expert committee,
the Pharmaceutical Beneﬁts Advisory Committee (PBAC). After a
positive recommendation by the PBAC and acceptance by the
minister, the price of the drug is set by negotiations between
the Pharmaceutical Beneﬁts Pricing Authority (PBPA) and the
sponsor company [14].
Since 1993, it is mandatory that the inclusion of a new drug
into the PBS is cost-effective when compared with existing drugs
in the scheme. It is only after the recommendation by the PBAC
of acceptable cost-effectiveness that the reimbursement price of
the drug is negotiated between the sponsor company and the
PBPA. In the assessment of cost-effectiveness, the cost of the new
drug used by the PBAC is based on that supplied by the sponsor
company. The cost of the drug is usually the uniform price as
requested by the global headquarters of the sponsor company to
be applied internationally. Sometimes, this may pose a problem
as the proposed price may not be considered to be cost-effective
in comparison with existing drugs for the same indication avail-
able in the PBS, but the sponsor company is reluctant or unable
to reach a reduced price with PBPA. This may sometimes result in
the drug not being included or delay of inclusion of the drug in
the PBS.
China
Before 2000, drug prices were set by local price authorities.
Afterward, the power of price setting moved upward to the
national planning committee, now called the State Development
and Reform Commission (SDRC) [15,16]. In recent years, the
Chinese government implemented a series of regulations and
legislations to control drug prices, such as pharmaceutical law,
decree of drug price administration, government pricing methods
for drugs, etc. In the past 10 years, the scope of price control in
terms of the number of drugs widened from 1500 items to 2400
items. Although these drugs represent only 20% of the total
medicines on the market, they make up approximately 60% of
the total pharmaceutical expenditure in China.
To make drug pricing more scientiﬁc and transparent, and
promote the equity of competition, the SDRC announced a
method for drug differential pricing and price ratios in 2005. A
drug’s differential price and price ratio comparison is deﬁned as
the price difference between forms, strengths, and packages of
the same medicine, which is inﬂuenced by average production
cost, production technique, the efﬁciency and effectiveness of
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clinical application, the convenience and treatment cost, etc. All
price reductions or adjustments by the government have followed
this policy. All chemical drugs in the same International Nonpro-
prietary Names (INN) should be classiﬁed as one drug [17]. The
World Health Organization (WHO) collaborates closely with
INN experts and national nomenclature committees to select a
single name of worldwide acceptability for each active substance
that is to be marketed as a pharmaceutical. The INN facilitate the
identiﬁcation of pharmaceutical substances or active pharmaceu-
tical ingredients. Each INN is a unique name that is globally
recognized and is public property. A nonproprietary name is also
known as a generic name.
In February of 2007, the SDRC published “Working Guide-
lines for Pharmaceutical Pricing”; it requires at least two pricing
professionals doing an in-depth study on the drug cost to the
pharmaceutical manufacturers and exchanging views with phar-
maceutical manufacturers. If needed, public hearings should be
organized by the discipline and supervision authority. The basic
data on pricing, suggestions, and recommendations for price
adjustments are presented during the hearings. Sometimes, these
hearings are open to the media, which allows for feedback from
the public. In February of 2007, the SDRC also formulated the
working rules on medical services and pharmaceuticals price. It
was pointed out that all prices set for medical services or phar-
maceuticals should go through the following ﬁve steps: 1) cost
investigation and audit; 2) market price investigation; 3) regional
coordination; 4) expert review and conﬁrmation; and ﬁnally, 5)
public hearing on the issues of price. The following criteria could
make pharmaceutical companies to apply some drugs to go
through a separated pricing mechanism; it will be based on
quality, efﬁcacy, safety, good clinical practice evidence, and
opinion from expert’s consultation.
In April of 2007, the China State Council (administration
branch of central government) expressed its determination to
further investigate and monitor the cost of medicines, improve
the pricing method, and expand the number of price control
drugs, speciﬁcally targeting prescription drugs [18].
For some medicines or new medicines without set prices,
manufacturers have the right to set their own prices, and then
report those prices to the provincial government. The Provincial
Price Bureau sets temporary prices in the record and reports them
to the central government. Most foreign pharmaceutical compa-
nies factor into the drug cost the expense of the sales team,
rebates, commissions, and promotions, thereby raising the
ex-manufacturer price. Another pricing behavior is that the
manufacturers widen the gap between the wholesale price and
real business price to the tenders, leaving an attractive proﬁt to
the tenders.
In pharmacoeconomic studies in China’s hospitals with a
fee-for-service payment system, drug costs, as part of direct
medical costs, are usually estimated based on acquisition (trans-
action) costs (i.e., the retail price of pharmaceuticals in hospi-
tals), which include the wholesale price plus a 15% to 25%
markup and rebates from pharmaceutical companies. The key
issues of cost estimation in pharmacoeconomic studies in China
are that some literature articles only consider acquisition (trans-
action) costs of drugs rather than total direct medical costs [19].
South Korea
In the Republic of Korea (South Korea), the NHI program is a
compulsory insurance plan for the whole population, except for
the lowest income households (1.8 million people, 3.6% of the
Korean population) who are covered by the Medical Aid
program. The two health insurance programs provide the same
beneﬁt package with fee-for-service type reimbursements for hos-
pital, physician, and pharmacy services [20]. The Health Insur-
ance Review Agency (HIRA) reviews all the claims and decides
the reimbursement amount, including the maximum allowable
cost (MAC) for all the pharmaceuticals (both Western and tra-
ditional medicines) listed by the NHI. The MAC is negotiated
with manufacturers based on the adjusted average price of seven
foreign countries (United States, UK, France, Japan, Germany,
Italy, and Switzerland). Then, the MAC is regularly reviewed, but
especially for any drug signiﬁcantly exceeding expected volume
or any drug with a MAC signiﬁcantly higher than the weighted
average of the surveyed acquisition cost (13 hospitals and 67
pharmacies were surveyed in 2007). Because MAC is publicly
available from the HIRA Web site (in Korean) [21], most Korean
researchers use the published MAC as the drug cost for their
pharmacoeconomic studies, which are rapidly growing in Korea
as a result of the positive list system (PLS) started in 2007, i.e.,
for any new drug, CEA is required to be listed to the NHI [22].
There are a couple of issues in using drug cost data from
Korea, including high generic drug prices and uncovered off-label
use. According to the recent Guidelines for Determining and
Adjusting New Medical Technologies (2006-123), the MAC of
the ﬁrst to the ﬁfth generic can be 68% of the original drug price
(which is lowered to 80% of the original price as soon as the ﬁrst
generic drug enters the market) and each following generic drug
can have 90% of the cheapest generic MAC previously available,
e.g., the sixth generic can have 61.2% of the original drug price,
the seventh generic can have 55.08% of the original drug price,
and so on. In addition, in Korea, any off-label use (including
on-label use exceeding dosage recommendation) of pharmaceu-
ticals is not eligible for reimbursement, and it is technically illegal
to charge any noneligible item as an out-of-pocket expense
without a special approval from the minister of health and
welfare (though this illegal practice exists). Hence, the Korean
Ministry of Health and Welfare has recently announced a plan to
legalize the off-label use of pharmaceuticals if the providers’
Institutional Review Board approves the off-label use and reports
to the HIRA within 10 days [23]. Nevertheless, any off-label use
is the patients’ out-of-pocket expense. Therefore, the HIRA is
able to monitor such use nationally each year and can eventually
convert it to an eligible coverage.
Western Europe
There are three main approaches to setting drug prices in Western
Europe, international reference pricing, reference-based reim-
bursement (clustering), and value-based approaches. Under inter-
national reference pricing, prices are set in relation to existing
prices in several selected “reference” countries. This approach is
popular in Southern Europe (e.g., Spain, Italy) because they are
not normally the ﬁrst countries to introduce new drugs, so there
are often existing prices to compare with. Normally, the jurisdic-
tions concerned base its prices on the average of those in the
reference countries, or they request a small discount on existing
prices. The main issues arising under this approach are: 1) the
choice of reference countries; and 2) the approach used for
currency conversions outside the Eurozone. Essentially, interna-
tional reference pricing emphasizes those countries that are ﬁrst
to introduce new products and their approach to setting prices.
Under reference-based reimbursement (clustering), similar
drugs are grouped and one price (i.e., reimbursement level) is set
for the group. Manufacturers are free to set their own price, but
they almost always gravitate to the reference price for fear of
losing market share as a result of higher co-pays. In most of the
countries operating such schemes, the approach is limited to
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drugs that are chemically equivalent, but in The Netherlands and
Germany, it has been extended to products that are deemed to be
“therapeutically” equivalent. The concept of equivalence may or
may not extend beyond a drug class.
In Germany, reference-based reimbursement becomes a pos-
sibility when the ﬁrst drug in a given class becomes generic. A
recent example is statins, where all were given a reference price
similar to the generic simvastatin, which was based on an evalu-
ation conducted by the Institute for Quality and Efﬁciency in
Healthcare. As a result, one of the newer statins, rosuvastatin,
was not launched in Germany as soon as in comparable coun-
tries. In The Netherlands, a new drug is placed in an existing
cluster unless the manufacturer claims that the product has
attributes that would justify a premium price. In these situations,
an economic evaluation is requested to support the claim. The
main issues arising under reference-based reimbursement are: 1)
how the judgments are made for therapeutic clustering (how
similar do drugs have to be); and 2) how is the price established
for the ﬁrst drug in a new cluster.
Finally, a number of approaches for assessing the cost-
effectiveness of drugs exist in Europe, although they have varying
degrees of transparency. Probably, the most transparent schemes
are those existing in Sweden and the UK. In these jurisdictions,
although the manufacturer is free to set the price of an individual
drug, the price of drugs is linked to cost-effectiveness to the
extent that the new product needs to demonstrate “adequate”
cost-effectiveness at the price the manufacturer wishes to charge.
Other countries operating similar schemes, although not neces-
sarily for all new products, include Belgium, Denmark, Finland,
and Portugal. Cost-effectiveness assessments are also undertaken
in these countries, although other factors may enter into the ﬁnal
pricing decision.
In addition, although not based on explicit assessments of
cost-effectiveness, the approach to pricing and reimbursement in
France awards a premium to drugs that are considered innova-
tive, and on occasion, companies may be asked to conduct post-
marketing studies to demonstrate some of the beneﬁts that are
claimed at the time of launch. Nevertheless, the extent to which
the agreements reached are truly value based or closer to simple
price–volume agreements is a matter for debate.
Literature
Currently, an increase in the number of pharmacoeconomic
studies being performed has been seen, but only a few of these
articles discusses how drug costs are estimated. These articles
include cost-beneﬁt analyses, cost-utility analyses, CEAs, and
those concentrating on drug price controls. An article by Francis
Pang states that there are a number of economic evaluations that
have not been published because of “compounds being termi-
nated in development, lengthy timetables for the implementation
of clinical trial programs, and commercial strategic issues.”
When Pang’s article was published in 2002, there were only 14
published empirical articles analyzing multinational pharmaco-
economic studies [24]. The pharmacoeconomic ﬁeld continues to
grow, which may lead to an increase in the number of articles
discussing price estimation in the future.
Currently, many of the studies published concentrate on the
United States and the European Union, but articles are rarely
found that look at other areas of the world. Reinharz et al. [25]
points out several obstacles of doing pharmacoeconomic
research in underdeveloped areas, such as Latin America. When
estimating costs in Latin America, speciﬁcally in Mexico and
Brazil, Reinharz found that management data were unsuitable to
provide valid information on costs and production. This article
illustrates the need for pharmacoeconomic research in other
areas of the world.
Currently Used Measures for Drug Cost
In the articles that discuss how costs are estimated, there are
several measures currently used, but one of the main ones is
purchasing power parities (PPPs) [5]. Nevertheless, there appears
to be limitations associated with each method. Providing inter-
national drug price comparisons is difﬁcult because every country
has their own pharmaceutical market basket [26]. Because of this
variability of medications between countries, Danzon and Kim
[5] proposed three measures that can be applied to different
strengths and doses of medications. These measures include, the
number of IMS standard units, the number of grams (kg) of
active ingredient, and the pack size of a drug. One of the limita-
tions found with these measurements is that they do not look at
the differences between generic and brand products. Another
widely used measure to estimate drug costs is the deﬁned daily
dose, which is deﬁned as the number of grams for either a normal
dose or recommended dose. This measurement was originally
recommended for use in multinational studies by the WHO [27]
because it provides a common measurement among countries
that otherwise are different. Nevertheless, this measure does not
adjust for duration of treatment. In a study completed for the
productivity report in Australia [28], price comparisons were
performed at the manufacturer level, using IMS health data,
which included mostly wholesale to retailer prices. Thus, there
are many measures used to estimate drug costs when performing
international studies, but each one has limitations that need to be
considered.
As part of the work of this Task Force, the European sub-
group reviewed the methods for estimating drug costs in 57
economic evaluations conducted in Denmark, Finland, Ireland,
Norway. and the UK. It was found that practice fell far short of
the ideal, with a substantial number of evaluations failing to
report the source of the drug costs, the route of administration,
the cost year, or whether the estimates took account of pharmacy
charges, sales taxes, wastage, or drug monitoring costs [29].
Controversies
Several controversies exist regarding drug costs in international
economic evaluations, but the main ones are generalizability and
validity. In this case, generalizability is deﬁned as the extent to
which the results in an evaluation are generalized from one
setting to another. It is not unusual for costs from one country in
a multinational trial to be used as a proxy for costs in other
countries [4]. This can result in biases on costs used and the
population examined, so a question that needs to be asked is if
the price levels are stable from one population to another [25].
Barbieri et al found that the key factor affecting the variation of
results from country to country seems to be whether resource use
is allowed to vary across countries [30]. Other generalizability
issues include, but are not limited to, the populations being
compared in terms of economic status and health insurance.
In addition to generalizability, validity is also a very contro-
versial topic in drug cost comparisons. The most discussed threat
to validity is the lack of representative samples used in pharma-
coeconomic analyses [4,24,25]. Danzon and Kim [5] point out
that generics are excluded in many of the analyses that estimate
costs, even though in some countries, generics constitute about a
third of pharmaceutical sales. Reinharz et al. [25] indicate that
validity problems in underdeveloped countries are due to poor
quality and accessibility of data. Another threat to validity is the
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comparison drugs used for analysis because comparisons involv-
ing cost data also bring up the issue of exchange rate conversions
because they ﬂuctuate daily [4]. Indeed, because pharmacoeco-
nomic studies estimate the incremental cost-effectiveness of the
new drug as compared with existing ones, the estimates can be
greatly inﬂuenced by differences in the prices of the older drugs
across countries, many of which are the result of exchange rate
ﬂuctuations. That is, while these drugs may have been priced at
a similar level in all countries at the time of launch, changes in the
relative value of currencies since that time may mean that prices
differ if converted at today’s relative values.
Discussion and Recommendations
The application of economic evaluation in drug pricing and
reimbursement is variable. An evaluation across nations reveals
that rank by price level does not correlate with rank for phar-
maceutical expenditures per capita, as expenditures are a func-
tion of differences in medical practice patterns and in social,
political, and economic values [31]. Therefore, economic evalu-
ation alone can not set a price for a medicine, because a decision
has to be made about the proportion of added value going to
society and the proportion going to the pharmaceutical company
as a reward for innovation [32]. Although beyond the scope of
this article, it would be interesting to assess whether countries
with a large stake in pharmaceutical R&D typically allow higher
prices for drugs than those countries that do not experience this
investment.
Differential pricing, based on Ramsey pricing principles, is the
second best efﬁcient way of paying for the global joint cost of
pharmaceutical R&D [33]. Danzon further argued that achieving
appropriate and sustainable price differences will require higher
income countries to forgo trying to “import” low drug prices for
low-income countries, through parallel trade and external refer-
encing. The WHO advocates both differential pricing and price
transparency.Nevertheless, price transparencymay jeopardize the
well meaning of increased access to pharmaceuticals in developing
countries [5]. International price comparisons, which can differ in
various sectors and suppliers in some developing countries, can
refer to some readily available/published sources (i.e., the Man-
agement Science for Health international drug price indicators
[34] and WHO/Health Action International manual [35]).
Variation of currency exchange rate may also inﬂuence the
methods to account for drug cost in pharmacoeconomic studies.
When the CEA analysis uses the exchange rate within a country,
the expected exchange rate ﬂuctuations have a similar effect on
all drugs sourced from the same country, which would probably
mean that the drug costs vary together in a similar magnitude.
This can be tested with a sensitivity analysis using different
multipliers for the drug costs. Nevertheless, the total costs in a
CEA involving international comparison would usually depend
on more than just drug costs, and the drug and other costs may
be differentially affected by exchange rate ﬂuctuations. To
prevent the large ﬂuctuations of exchange rates, the PPP
calculation/conversion is suggested as an alternative sensitivity
analysis. Nevertheless, researchers should be aware of the limi-
tations of using the PPP, which resulted from the strictest assump-
tions that the real value placed on goods and services are
homogeneous across countries and goods markets are perfect
(i.e., international shipment of goods able to take place freely,
instantaneously, and without cost).
Finally, as mentioned above, in several European countries,
most notably The Netherlands (through the Health Care Insur-
ance Board), Sweden (through the Dental and Pharmaceutical
Beneﬁts Agency), and England (through the National Institute
for Health and Clinical Excellence), there has been a trend
toward value-based pricing. The ﬁrst step has been to conduct
pharmacoeconomic studies to establish the value of new drugs
and, by implication, to assess whether there is any justiﬁcation
for a price premium over and above existing drugs for the con-
ditions concerned. Currently, drug costs included in pharmaco-
economic studies are based on the price proposed by the
manufacturer. Nevertheless, in the future, it is possible that the
pharmacoeconomic studies form the basis for price negotiations.
In England, the suggestion is that a value-based price could be
established for each indication in which the drug is used, with a
higher price being allowed for those indications where more
value is added [36].
Task Force Recommendations
In summary, a few points regarding drug cost need to be consid-
ered in conducting pharmacoeconomic analysis or international
drug comparison:
• Drug units should be standardized in terms of volume of
active ingredient, regardless of package and dosing strength
variations across countries.
• Drug costs should be measured in local currency per unit of
active ingredient and should be converted to other curren-
cies using sensitivity analyses of PPP and exchange rate,
whichever is more appropriate.
• When using drug prices from different years, the consumer
price index for the local currency should be applied before
the PPP and/or exchange rate conversion.
• A modiﬁed social perspective should be employed where
drug costs should reﬂect the best pricing available to the
government or other large third-party payers in the country.
• Drug costs should be kept as transparent as possible.
• The type of drug pricing (value-based, reference pricing,
market pricing, MAC, etc.) should be clearly identiﬁed in
the pharmacoeconomic application.
• ISPOR should maintain a Web site indicating how drug
prices are determined in each country and region, to be
updated periodically by the ISPOR Task Force on Good
Research Practices—Use of Drug Costs for Cost Effective-
ness Analysis (DCTF).
Source of ﬁnancial support: The article is prepared without a contract or
funding from a sponsor nor contingent on the sponsor’s approval.
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